Under the deal IMS will integrate its evidence-based, anonymised patient and treatment outcome insights with TTC’s cost data. This is drawn from a collection of organisations that the firms claim between them conduct nearly 80% of all commercial clinical studies.

The companies say the combination will enable pharma R&D teams to improve the productivity of their clinical trials using advanced analytics and decision-support tools.

“This acquisition marks an important step in further expanding IMS’s capabilities in the pharma R&D space,” says Andrew Kress, senior vice president, healthcare value solutions, IMS. “The combination of TTC’s portfolio and IMS information assets will fuel ongoing innovation, enabling clients to base vital budgeting and negotiation decisions on real-world data and benchmarks.”